The RNAi field is experiencing a sharp capital and dealmaking surge. City Therapeutics raised about USD 230 million in an IPO after a USD 135 million Series A in 2024 and a USD 99.5 million Series B in 2026, with pipeline assets including CITY-FXI, a Factor XI RNAi programme in Phase I, and CITY-RBP4, a potential first-in-class RBP4-targeting therapy for Stargardt disease.
On 19 October, Merck KGaA agreed to acquire Silence Therapeutics for about USD 1.3 billion, while ADARx Pharmaceuticals raised more than USD 500 million via IPO on 1 October and Souffle Therapeutics closed a USD 135 million Series B on 13 October, showing that next-generation delivery, stabilisation and extrahepatic targeting have reopened investor appetite for nucleic-acid medicines.

Email us at pmc@pharmcube.com for a free database trial, exclusive reports, or a 1-on-1 consultation